A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

• Status: Recruiting
• Trial end date: 2025-04-18
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborators: Innovative Therapies for Children with Cancer in Europe (ITCC); New Approaches to Neuroblastoma Therapy Consortium (NANT)
• Treatments: Cyclophosphamide; Topotecan

Criteria

Inclusion Criteria:

• Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.

• Participants must be able to swallow capsules.

Exclusion Criteria:

• Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.

• Participants must not have untreated tumor that has spread to the brain or spinal cord.

• Participants must not have a serious active disease other than neuroblastoma.

• Participants must not have a condition affecting absorption.

• Participants must not have had prior aurora kinase inhibitor exposure.

• Participants must not have a known allergy to the study treatment.

• Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.